GM Advisory Group’s Xeris Biopharma Holdings XERS Stock Holding History

GM Advisory Group’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$49K	–	219
2021 Q3	$49K	Hold	20,000	–	–	﹤0.01%	196
2021 Q2	$81K	Hold	20,000	–	–	0.01%	199
2021 Q1	$90K	Buy	+20,000	New	+$108K	0.01%	192

Other funds holding XERS

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

GM Advisory Group's XERS Position: Q4 2021 in Review

GM Advisory Group sold out of Xeris Biopharma Holdings (XERS) in Q4 2021, closing a stake of 20,000 shares — an estimated $49K sold.

GM Advisory Group first reported a position in XERS in Q1 2021 and held it in 3 quarters. The position peaked at $90K in Q1 2021. 92 funds tracked by Wall St. Rank hold XERS as of Q4 2021.

GM Advisory Group reported no remaining Xeris Biopharma Holdings position as of Q4 2021 after selling out during the quarter.
GM Advisory Group sold 20,000 Xeris Biopharma Holdings shares in Q4 2021, an estimated $49K.
GM Advisory Group first reported a position in Xeris Biopharma Holdings in Q1 2021 and held it in 3 quarters.
GM Advisory Group's Xeris Biopharma Holdings position peaked at $90K in Q1 2021.
92 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2021.

Based on GM Advisory Group's 13F filing for Q4 2021, filed 10 Feb 2022.